The bidding window for Jay Ambe Supermarkets SME IPO was open from September 10, 2025, to September 12, 2025. The basis of allotment will be finalised today, September 15, 2025. Here’s how you can check the IPO allotment status on the BSE and registrar’s website.
Jay Ambe Supermarkets IPO is a book-building issue of ₹18.45 crores, consisting entirely of a fresh issue of ₹0.24 crore shares. The price band is set at ₹74.00 to ₹78.00 per share. The tentative listing on BSE SME is September 17, 2025.
Beeline Capital Advisors Pvt. Ltd. is the book-running lead manager, and MUFG Intime India Private Limited is the registrar for the issue.
The net proceeds from the fresh issue will be used towards:
(September 12, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
16.79 |
Non-Institutional Investors |
110.24 |
Individual Investors (IND category bidding for 2 Lots) |
71.39 |
Total |
64.13 |
As of 15 September 2025, Jay Ambe Supermarkets' IPO GMP stood at ₹8. The estimated listing price is ₹86, i.e., a gain of 10.26% per share.
Source: Investorgain Media Report dated 15 September 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Jay Ambe Supermarkets operates in the retail sector. The company operates under the brand name City Square Mart, which opened its first store in August 2018 in Kudasan, Gandhinagar. Since then, the brand has expanded significantly, establishing a strong presence across Gujarat with a total of 17 stores and over 96,876 square feet of retail space.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.